Beijing, China
Coyote Bioscience Co., Ltd. (“Coyote”) is a Chinese biotechnology company established in 2009 and based in Beijing. Specializing in molecular diagnostics, the company has made significant advancements in fast nucleic acid detection technology for microorganisms. Recognized as a national high-tech enterprise, Coyote has garnered accolades such as “China’s Top 50 Most Valuable Enterprises for Investment” and “China’s Most Promising Enterprise”. Notably, the company was honored as an "Advanced Collective" by the Ministry of Industry and Information Technology for its efforts in combating the COVID-19 pandemic in 2020.
With a focus on R&D, Coyote has amassed a portfolio of 83 domestic and international patents, including 22 international PCT patents, 13 domestically authorized patents, 2 US patents, and 1 Australian patent. The company's commitment to innovation is underscored by its participation in the Torch Program of the Ministry of Science and Technology and national major programs for infectious diseases.
Having secured a CNY50.00M Series E investment on 28 March 2019, Coyote has attracted investment from prominent firms such as Hillhouse Capital, Northern Light Venture Capital, SAIF Partners, and Legend Star. The company's management and technical teams comprise graduates from esteemed institutions in China and abroad, with collaborations extending to influential academicians in the field.
The company's slogan, "Molecular Diagnostics for Everyone," epitomizes its corporate vision, reflecting its dedication to advancing molecular diagnostics in the biotechnology industry.
